Patents Examined by Jason M. Nolan
  • Process for preparing azabicyclic compounds
    Patent number: 8461352
    Abstract: The present invention relates to a process for preparing azabicyclic compounds that are useful intermediates for synthesizing pharmaceutical compounds or salts thereof.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: June 11, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Narendra Bhalchandra Ambhaikar, Brian Richard Bear, Lev T. D. Fanning, Robert Hughes, Benjamin Littler
  • Halosubstituted aryloxyalkylimidazolines for use as pesticides
    Patent number: 8455663
    Abstract: The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: June 4, 2013
    Assignee: Syngenta Crop Protection LLC
    Inventors: Anthony Cornelius O'Sullivan, Thomas Pitterna, Jürgen Harry Schaetzer, Christoph Luethy
  • Dendrimer conjugates
    Patent number: 8445528
    Abstract: The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: May 21, 2013
    Assignee: The Regents of the University of Michigan
    Inventors: James R. Baker, Jr., Xue-min Cheng, Thommey P. Thomas, Baohua Mark Huang
  • Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
    Patent number: 8445507
    Abstract: A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: May 21, 2013
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Crystalline sodium atorvastatin
    Patent number: 8440712
    Abstract: Crystalline sodium atorvastatin, compositions containing the same and methods for the production thereof.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: May 14, 2013
    Assignees: Arrow International Limited, Zhejiang Neo-Dankong Pharmaceutical Co. Ltd.
    Inventors: Kailan Zhou, Hong Liu, Zhirong Chen, Huabin Hong, Yang Sun, Yunde Wang, Jiangchun Pan
  • Inhibitors of serine proteases
    Patent number: 8440706
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: May 14, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Arnaud Le Tiran, Emanuele Perola
  • Heteroleptic pyrrolecarbaldimine precursors
    Patent number: 8431719
    Abstract: Disclosed are precursors having a pyrrolecarbaldiminates ligand and methods of synthesizing the same. The pyrrolecarbaldiminates ligand may be substituted.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: April 30, 2013
    Assignee: American Air Liquide, Inc.
    Inventors: Andrey V. Korolev, Clément Lansalot-Matras
  • Process for the preparation of 5-(2-ethyl-dihydro-1-inden-2-yl)-1-imidazole and salts thereof
    Patent number: 8431717
    Abstract: The invention provides an improved, highly efficient method for preparing 5-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole, and its salts, in particular its pharmaceutically acceptable salts.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: April 30, 2013
    Assignee: JSC Grindeks
    Inventors: Viesturs Lusis, Dzintra Muceniece, Inese Reine, Armands Zandersons
  • Process for production of optically active fluoroamine
    Patent number: 8426645
    Abstract: Disclosed is a process for producing a protected optically active fluoroamine, which comprises the step of reacting an imine-protected optically active hydroxyamine, an oxazolidine-protected optically active hydroxyamine, or a mixture of the imine-protected optically active hydroxyamine and the oxazolidine-protected optically active hydroxyamine, with sulfuryl fluoride (SO2F2) in the presence of a tertiary amine having a carbon number of 7 to 18 (produced by substituting all of three hydrogen atoms in ammonia by alkyl groups). The desired optically active fluoroamine can be produced by hydrolyzing the protected optically active fluoroamine under acidic conditions.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: April 23, 2013
    Assignee: Central Glass Company, Limited
    Inventors: Akihiro Ishii, Takako Yamazaki, Manabu Yasumoto
  • Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
    Patent number: 8426587
    Abstract: The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: (I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: April 23, 2013
    Assignee: Pharmaxis Ltd.
    Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot
  • Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK
    Patent number: 8420816
    Abstract: Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: April 16, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Toufike Kanouni, John David Lawson, Michael B. Wallace
  • Electrolyte additive of dye-sensitized solar cell and method of making the same
    Patent number: 8410283
    Abstract: An electrolyte additive is selected from N-alkyl benzimidazole derivatives and is applicable to dye-sensitized solar cells. Accordingly, the electrolyte additive can be added to electrolyte at low concentration, and loss of function due to crystallization after long-term use can be prevented; in addition, short circuit photocurrent density and solar energy-to-electricity conversion efficiency of solar cells incorporating the electrolyte additive can be increased.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: April 2, 2013
    Assignee: National Taipei University of Technology
    Inventors: Sheng-Tung Huang, Chung-Kuang Yang
  • Hydrated sodium salt form of celecoxib
    Patent number: 8410287
    Abstract: Hydrated celecoxib sodium salt forms and processes to prepare hydrated celecoxib sodium salt forms are disclosed. The celecoxib sodium salt forms are particularly useful and suitable for pharmaceutical applications.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: April 2, 2013
    Assignee: McNeil-PPC, Inc.
    Inventors: Julius F. Remenar, Mark D. Tawa, Matthew L. Peterson
  • Aryl sulfonamide amine compounds and their use as 5-HT6 ligands
    Patent number: 8404720
    Abstract: The present invention relates to novel aryl sulfonamide amine compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: March 26, 2013
    Assignee: Suven Life Sciences Limited
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Rama Sastri Kambhampati, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
  • Compounds and preparation for montelukast sodium
    Patent number: 8399675
    Abstract: This invention relates to novel compounds and a process for preparation of montelukast sodium.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: March 19, 2013
    Assignee: Formosa Laboratories, Inc.
    Inventors: Jui-Te Hung, Ching-Peng Wei
  • Fused pyrrolocarbazoles
    Patent number: 8383813
    Abstract: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: February 26, 2013
    Assignee: Cephalon, Inc.
    Inventors: Nadine C. Becknell, Peter D. Brown, Reddeppareddy Dandu, James L. Diebold, Diane E. Gingrich, Robert L. Hudkins, Bruce A. Ruggeri, Ming Tao, Theodore L. Underiner, Allison L. Zulli
  • Method for producing optically active amino acid derivative
    Patent number: 8383833
    Abstract: The present application relates to a method for producing an optically active ?-amino acid derivative, comprising steps of reacting an ?-haloester derivative represented by the general formula (1): of which alcohol part of the ester group is an optically active alcohol derivative, with an amine compound; then deprotecting the obtained compound; further carrying out an ester exchange reaction. According to the present invention method, it is possible to easily produce an optically active ?-amino acid ester derivative which is useful as an intermediate for drugs with high selectivity.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: February 26, 2013
    Assignee: Kaneka Corporation
    Inventors: Shohei Yamamoto, Akio Fujii, Masaru Mitsuda
  • Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
    Patent number: 8378137
    Abstract: Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: February 19, 2013
    Assignee: XenoPort, Inc.
    Inventors: Mark A. Gallop, Xuedong Dai, Randall A. Scheuerman, Stephen P. Raillard, Suresh K. Manthati, Fenmei Yao, Thu Phan, Maria Ludwikow, Ge Peng, Seema Bhat
  • Inhibitors of serine proteases
    Patent number: 8372873
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: February 12, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Arnaud Le Tiran, Emanuele Perola
  • Method of manufacturing a ruthenium complex
    Patent number: 8362266
    Abstract: A method of making an alkali metal salt of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] is disclosed.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: January 29, 2013
    Assignee: Niiki Pharma Inc.
    Inventor: Berhhard Keppler